Selected data models

You must log in to select data models for download or further analysis.

5 Search results.
Relevance Rating New first Old first

Infanrix Vaccine - 102038 - Study Conclusion

- 3/11/18 - 1 form, 4 itemgroups, 16 items, 1 language
Itemgroups: Header, Serious adverse event, Elimination criteria, Study Conclusion
Open, phase IV clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ Infanrix™ (DTPa) vaccine administered as a booster dose at 4 years of age in preterm vs. full-term children previously primed and boosted with Infanrix™ hexa.

Infanrix Vaccine - 102038 - Visit 2

- 3/11/18 - 1 form, 3 itemgroups, 11 items, 1 language
Itemgroups: Header, Check for Study Continuation, Laboratory Tests
Open, phase IV clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ Infanrix™ (DTPa) vaccine administered as a booster dose at 4 years of age in preterm vs. full-term children previously primed and boosted with Infanrix™ hexa.

Infanrix Vaccine - 102038 - Additional Forms

- 3/11/18 - 1 form, 7 itemgroups, 50 items, 1 language
Itemgroups: Header, Report Swelling, Concomitant Vaccination, Concomitant vaccination, Medication, Medication, Non-serious Adverse Events
Open, phase IV clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ Infanrix™ (DTPa) vaccine administered as a booster dose at 4 years of age in preterm vs. full-term children previously primed and boosted with Infanrix™ hexa.

Infanrix Vaccine - 102038 - Elegibility Questionnaire

- 3/4/18 - 1 form, 3 itemgroups, 16 items, 1 language
Itemgroups: Elegibility Question, Inclusion Criteria, Exclusion Criteria
Open, phase IV clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ Infanrix™ (DTPa) vaccine administered as a booster dose at 4 years of age in preterm vs. full-term children previously primed and boosted with Infanrix™ hexa.

Infanrix Vaccine - 102038 - Visit 1

- 3/4/18 - 1 form, 9 itemgroups, 26 items, 1 language
Itemgroups: Header, Informed consent, Demographics, Eligibility Criteria, General Medical History / Physical Examination, General medical history / physical examination, Pre-vaccination assessment, Vaccine Administration, Vaccine not administered
Open, phase IV clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ Infanrix™ (DTPa) vaccine administered as a booster dose at 4 years of age in preterm vs. full-term children previously primed and boosted with Infanrix™ hexa.

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial